ArticleRheumatology and therapy2026
Frequency and Impact of Serious Infections in Hospitalised Patients with Sjögren's Disease: A Longitudinal Cohort Study.
Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAs little is known about the risk, type and severity of infections in patients with Sjögren's disease (SjD), we compared the frequency and impact of serious infections (SI) between hospitalised patients with SjD and controls (Co).
methodsPopulation-level observational study of patients with SjD (n = 692, 87.9% female, age 67 years) identified in the Hospital Morbidity Data Collection (HDMC) in Western Australia (WA) between 1980 and 2015 by diagnostic codes (ICD-9 CM 710.2, ICD10-AM M35.0) and age- and gender-matched controls free of rheumatic disease (n = 3737, 87.5% female, age 67 years). SI were defined by a validated algorithm and primary SjD, as the absence of other autoimmune rheumatic disease. Odds ratios (OR), incidence rates (IR) per 100 person-years (PY) and IR ratios (IRR) with 95% CI for SI were estimated. HDMC data were linked to WA Death Registry to evaluate the impact of SI on mortality rates (MR) per 100 PY and Kaplan-Meier survival estimates.
resultsSerious infections occurred more in patients with SjD (OR 1.87, CI 1.59, 2.21, p < 0.01) with a fourfold higher IR for SI (IRR 4.28, CI 4.02-4.56) and increased IRR for pneumonia (4.01, CI 3.50-4.60), urogenital (3.06, CI 2.73-3.43), skin/soft tissue (5.22, CI 4.60-5.90), opportunistic infections (6.93, CI 5.77-8.32) and sepsis (6.15, CI 4.87-7.74) (all p < 0.01). The MR for patients with SjD with SI was almost twice that for Co with SI (MR ratio 1.89, CI 1.65-2.16). Patients with associated SjD (n = 270, 39%) had increased OR (2.05, CI 1.49-2.82) and IRR (1.61, CI 1.44-1.79) for SI compared to patients with primary SjD (n = 422, 61%). Few differences in SI existed between patients with SjD associated with rheumatoid arthritis (n = 197) or SLE (n = 79).
conclusionsSI occurred at a higher rate in all patients with SjD and was associated with increased long-term mortality. These results emphasize the increased susceptibility to and impact of SI for both patients with primary and secondary SjD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.